Gabriel Virella to Glycation End Products, Advanced
This is a "connection" page, showing publications Gabriel Virella has written about Glycation End Products, Advanced.
Connection Strength
0.846
-
Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93.
Score: 0.190
-
High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
Score: 0.118
-
Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec; 231(2):315-22.
Score: 0.101
-
Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74.
Score: 0.096
-
High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40.
Score: 0.091
-
High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
Score: 0.087
-
Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67.
Score: 0.053
-
Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003 Jul; 10(4):499-505.
Score: 0.049
-
Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
Score: 0.037
-
The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
Score: 0.023